-
Contemporary Management and Outcomes of Veterans Hospitalized With Alcohol Withdrawal: A Multicenter Retrospective Cohort Study. J. Addict. Med. (IF 5.5) Pub Date : 2024-03-07 Matthew V Ronan, Kirsha S Gordon, Melissa Skanderson, Michael Krug, Patrick Godwin, Daniel Heppe, Matthew Hoegh, Joel C Boggan, Jeydith Gutierrez, Peter Kaboli, Micah Pescetto, Michelle Guidry, Peter Caldwell, Christine Mitchell, Erik Ehlers, Nazima Allaudeen, Jessica Cyr, Andrea Smeraglio, Peter Yarbrough, Richard Rose, Anand Jagannath, Jaclyn Vargas, Paul B Cornia, Meghna Shah, Matthew Tuck, Cherinne
Few studies describe contemporary alcohol withdrawal management in hospitalized settings or review current practices considering the guidelines by the American Society of Addiction Medicine (ASAM).
-
A Quantitative Examination of Illness Models Among People With Opioid Use Disorder Receiving Methadone Treatment. J. Addict. Med. (IF 5.5) Pub Date : 2024-03-06 Marina Gaeta Gazzola, Iain D Carmichael, Emma Thompson, Mark Beitel, Lynn M Madden, Gul Saeed, Kim Hoffman, Muhammad Hammouri, Connie Hsaio, Declan T Barry
Few studies have examined illness models among people with addiction. We investigated illness models and their associations with demographics and treatment beliefs among patients receiving methadone treatment for opioid use disorder.
-
Impact of Nicotine Replacement Therapy Sampling on Cessation-Related Processes. J. Addict. Med. (IF 5.5) Pub Date : 2024-03-06 Michelle L Sisson, Jamie M Gajos, Caitlin Wolford-Clevenger, Keith R Chichester, Elizabeth S Hawes, Samantha V Hill, Richard C Shelton, Peter S Hendricks, Michael S Businelle, Matthew J Carpenter, Karen L Cropsey
Smoking prevalence remains high among low-income smokers. Understanding processes (eg, withdrawal, craving, motivation) in early smoking cessation is crucially important for designing effective interventions for this population.
-
Prevalence of Kratom Use Disorder among Kratom Consumers. J. Addict. Med. (IF 5.5) Pub Date : 2024-03-05 Katherine Hill, Oliver Grundmann, Kirsten E Smith, Corneliu N Stanciu
Kratom leaf products are increasingly consumed in the United States, with many consumers reporting they experience beneficial effects from kratom use. However, there is a growing concern for kratom's potential to result in dependence when used regularly. As such, we sought to assess, using Diagnostic and Statistical Manual of Mental Disorders, (DSM-5), diagnostic criteria for substance use disorder
-
A Nationwide Survey Study of Recovery Community Centers Supporting People in Recovery From Substance Use Disorder. J. Addict. Med. (IF 5.5) Pub Date : 2024-03-01 Bettina B Hoeppner, Hazel V Simpson, Catherine Weerts, Marion J Riggs, Alivia C Williamson, Diadora Finley-Abboud, Lauren A Hoffman, Philip X Rutherford, Patty McCarthy, Julia Ojeda, Amy A Mericle, Vinod Rao, Brandon G Bergman, Akosua B Dankwah, John F Kelly
The medical community has become aware of its role in contributing to the opioid epidemic and must be part of its resolution. Recovery community centers (RCCs) represent a new underused component of recovery support.
-
Temporal Trends in Methamphetamine Use in Patients Admitted to the Hospital: A Retrospective Cohort Study. J. Addict. Med. (IF 5.5) Pub Date : 2024-02-29 Daniel J Suto, Jessica Xiao, Amy L Bellinghausen, Mazen Odish, Daniel A Sweeney, Gabriel Wardi, Robert L Owens
Although methamphetamine use is common, the scope of methamphetamine use and outcomes for patients admitted to the hospital is unclear. This study aims to identify the prevalence of methamphetamine use from January 2012 to January 2022, coingestions, hospital course, and readmission rate of admitted patients.
-
Global and Regional Burden and Trend of Neoplasms Attributable to Alcohol Consumption in the Past 3 Decades. J. Addict. Med. (IF 5.5) Pub Date : 2024-02-26 Hui-Wen Song, Jin-Hua Ge, Bi-Xia Xie, Mei-Ting Jiang, Jin-Shui Pan
To provide valuable insights for targeted cancer screening among high-risk patients, we analyzed the global and regional burden of neoplasms resulting from alcohol consumption between 1990 and 2019.
-
"The Only Reason I Am Willing to Do It at All": Evaluation of VA's SUpporting Primary care Providers in Opioid Risk reduction and Treatment (SUPPORT) Center. J. Addict. Med. (IF 5.5) Pub Date : 2024-02-22 Emily C Williams, Madeline C Frost, Anissa N Danner, Aline M K Lott, Carol E Achtmeyer, Carly L Hood, Carol A Malte, Andrew J Saxon, Eric J Hawkins
Medication treatment for opioid use disorder (MOUD) is effective and recommended for outpatient settings. We implemented and evaluated the SUpporting Primary care Providers in Opioid Risk reduction and Treatment (SUPPORT) Center-a quality improvement partnership to implement stepped care for MOUD in 2 Veterans Health Administration (VA) primary care (PC) clinics.
-
A Brief Screening Tool for Risk of Self-Medication of Pain with Substance Use. J. Addict. Med. (IF 5.5) Pub Date : 2024-02-14 Nicholas J Bush, Erin Ferguson, Emily Zale, Jeff Boissoneault
Substance use and pain are both growing public health concerns globally. Evidence suggests that individuals may use substances in order to self-medicate their pain. The Catastrophizing, Anxiety, Negative Urgency, and Expectancy model was developed to provide a theoretical foundation for the modifiable risk factors implicated in self-medication of pain with substance use. This study aimed to use the
-
Case Series of Individuals Treated with Naltrexone during Pregnancy for Opioid and/or Alcohol Use Disorder. J. Addict. Med. (IF 5.5) Pub Date : 2024-02-14 Elisha M Wachman, Kelley Saia, Jonathan Bressler, Martha Werler, Ginny Carter, Hendree E Jones
There is a lack of knowledge about the relative safety and efficacy of naltrexone for the treatment of pregnant individuals with opioid and/or alcohol use disorder, including the range of outcomes, in both the pregnant individual and the infant, over the course of peripartum period. Our objective was to describe these outcomes in a cohort of pregnant individuals on naltrexone.
-
Mapping Buprenorphine Access at Philadelphia Pharmacies. J. Addict. Med. (IF 5.5) Pub Date : 2024-02-12 Shoshana V Aronowitz, Rachel French, Allison Schachter, Emily Seeburger, Nicole O'Donnell, Jeanmarie Perrone, Margaret Lowenstein
Buprenorphine is not reliably stocked in many pharmacies, and pharmacy-level barriers may deter patients from opioid use disorder care. We surveyed all outpatient pharmacies in Philadelphia to describe variation in buprenorphine access and developed a map application to aid in identifying pharmacies that stock the medication.
-
The Devil's in the Depot Details: Case of Iatrogenic Opioid Intoxication After Buprenorphine Injection Requiring Surgical Excision. J. Addict. Med. (IF 5.5) Pub Date : 2024-02-12 Simone Vais, Nichole Starr, Maria Castro, Nathan Brand, Alexander Murphy, Ronald Tesoriero, Irina Kryzhanovskaya
Monthly long-acting injectable buprenorphine (LAI-BUP) is a treatment option for moderate to severe opioid use disorder. Safe administration of LAI-BUP requires preexisting opioid tolerance to prevent sedation and respiratory depression. In the event of adverse medication effects including oversedation, LAI-BUP can be surgically excised up to 14 days after administration (https://www.sublocadehcp.
-
Treatment of Gamma Hydroxybutyrate Withdrawal in a Pregnant Female-A Case Report. J. Addict. Med. (IF 5.5) Pub Date : 2024-02-12 Shannon Joyce, Sarah Lea, Megan Woolner, Amanda Leddy
Gamma hydroxybutyrate (GHB) is used illicitly for its sedative hypnotic effects, and those who take it regularly are at risk of developing a substance use disorder. Withdrawal from GHB can include severe symptoms that may require medical management. For GHB use and withdrawal during pregnancy, there are no evidence- or practice-based guidelines to follow, and there is only minimal research literature
-
North Carolina Medicaid System Perspectives on Substance Use Disorder Treatment Policy Changes during the COVID-19 Pandemic. J. Addict. Med. (IF 5.5) Pub Date : 2024-02-12 Phillip M Hughes, Caleb W Easterly, Kathleen C Thomas, Christopher M Shea, Marisa Elena Domino
This study aimed to describe perspectives from stakeholders involved in the Medicaid system in North Carolina regarding substance use disorder (SUD) treatment policy changes during the coronavirus disease 2019 pandemic.
-
Buprenorphine Receipt and Retention for Opioid Use Disorder following an Initiative to Increase Access in Primary Care. J. Addict. Med. (IF 5.5) Pub Date : 2024-02-08 Eric J Hawkins, Carol A Malte, Hildi J Hagedorn, Adam J Gordon, Emily C Williams, Ryan S Trim, Brittany E Blanchard, Aline Lott, Anissa N Danner, Andrew J Saxon
Buprenorphine, a medication for opioid use disorder (OUD), is underutilized in general medical settings. Further, it is inequitably received by racialized groups and persons with comorbidities. The Veterans Health Administration launched an initiative to increase buprenorphine receipt in primary care. The project's objective was to identify patient-related factors associated with buprenorphine receipt
-
Novel Uses of Methadone Under the "72-Hour Rule" to Facilitate Transitions of Care and Low-Dose Buprenorphine Induction in an Outpatient Bridge Clinic. J. Addict. Med. (IF 5.5) Pub Date : 2024-02-08 Minaliza Shahlapour, Sabetta Singh, Paul J Christine, Jordana Laks, James Evans, Natalija M Farrell, G Karim Khan, Jessica L Taylor, Hallie Rozansky
Federal regulations restrict methadone for opioid use disorder (OUD) treatment to licensed opioid treatment programs (OTPs). However, providers in other settings can administer methadone for opioid withdrawal under the "72-hour rule" while linking to further care. Prior work has demonstrated that methadone initiation in a low-barrier bridge clinic is associated with high OTP linkage and 1-month retention
-
Self-fulfilling Prophecy: Does Structural and Interpersonal Bias Against Pregnant and Postpartum People With Substance Use Disorders Undermine Parenting Identity? J. Addict. Med. (IF 5.5) Pub Date : 2024-2-5 Daisy Goodman
Pregnant and parenting people with substance use disorders are a highly stigmatized group. Structural and interpersonal bias contribute to reluctance to engage in prenatal, postpartum, and well-child care for this population. Two studies described in this issue of the Journal of Addiction Medicine explore the implications of health care provider-family relationships on experience of care for birthing
-
Social Determinants of Health and Continuity of Medications for Opioid Use Disorder Among Patients Receiving Treatment in Rural Primary Care Settings. J. Addict. Med. (IF 5.5) Pub Date : 2024-02-05 Huyen Pham, Allison Ober, Laura-Mae Baldwin, Larissa J Mooney, Yuhui Zhu, Zhe Fei, Yih-Ing Hser
Factors associated with treatment retention on medications for opioid use disorder (MOUD) in rural settings are poorly understood. This study examines associations between social determinants of health (SDoH) and MOUD retention among patients with opioid use disorder (OUD) in rural primary care settings.
-
Intersectional Risk and the Significant Gap in Care for Persons with Co-occurring Chronic Pain and Opioid Withdrawal. J. Addict. Med. (IF 5.5) Pub Date : 2024-02-05 Orrin D Ware, Andrew S Huhn, Jennifer D Ellis, H Elizabeth Bird, Chung Jung Mun, Kelly E Dunn
Persons with chronic pain and women tend to enter treatment for opioid use disorder with greater opioid withdrawal severity than persons without chronic pain and men, respectively. This study examined characteristics of facilities with opioid withdrawal treatment, including gender-based services, as a function of whether they reported having a tailored pain management program.
-
Comparing the Performance of World Mental Health Composite International Diagnostic Interview Substance Abuse Module in Adolescents to Diagnoses Made by Pediatric Addiction Medicine Specialists. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-30 Sharon Levy, Machiko Minegishi, Melissa Brogna, Geetha Subramaniam, Jennifer McCormack, Roger Weiss, Elissa R Weitzman
The World Mental Health Composite International Diagnostic Interview Substance Abuse Module (WMH-CIDI-SAM) is commonly used as a criterion standard measure for substance use disorder (SUD) diagnoses, although the accuracy of this tool when used with adolescents is unknown. The objective of this study was to evaluate the agreement between SUD diagnoses for adolescents made by WMH-CIDI-SAM and those
-
Xylazine Use among People Who Inject Drugs, Philadelphia 2022. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-30 Marissa Tan, Tanner Nassau, Danica Kuncio, Dana Higgins, Daniel Teixeira da Silva, David Tomlinson, Kathleen A Brady
Xylazine is commonly mixed with illicit opioids in Philadelphia, and potential associations with wound issues, infectious diseases, and overdoses are of public health concern. We used data from the National HIV Behavioral Surveillance Survey among persons who inject drugs (PWIDs) in Philadelphia to better identify individuals at risk and inform patients and clinicians about xylazine risk factors.
-
Trajectories of Opioid Misuse and Opioid Use Disorder Among Adults With Chronic Pain and HIV: An Observational Study. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-25 Hector R Perez, Yuting Deng, Chenshu Zhang, Justina L Groeger, Matthew Glenn, Emma Richard, Ariana Pazmino, Ana Alicia De La Cruz, Melanie Prinz, Joanna L Starrels
In a longitudinal cohort of patients with HIV and chronic pain, we sought to (1) identify trajectories of opioid misuse and opioid use disorder (OUD) symptoms, and to (2) determine whether prescription opioid dose was associated with symptom trajectories.
-
Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-23 Hamzah Bakouni, Lexie Haquet, M Eugenia Socias, Bernard Le Foll, Ron Lim, Keith Ahamad, Didier Jutras-Aswad
Methadone and buprenorphine/naloxone (BUP/NX) titration parameters (eg, range, duration, and rate) can vary during opioid use disorder (OUD) treatment. We describe methadone and BUP/NX titration patterns and their associations with treatment outcomes among individuals with a prescription-type OUD.
-
Postpartum Treatment for Chronic Hepatitis C Virus Among People With Opioid Use Disorder: A Prospective Pilot Clinical Trial. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-23 Catherine A Chappell, Ellen Stewart, Hollis J Laird, Naudia Jonassaint, Katelyn Kasula, Maya Patterson, Elizabeth E Krans
The objective of this study was to evaluate the feasibility and acceptability of postpartum hepatitis C virus (HCV) treatment integrated within a substance use treatment program for pregnant and postpartum people with opioid use disorder (OUD).
-
Exploration into Patterns of Cannabis Use across Pregnancy and Postpartum. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-23 Anna E Eitel, Sara M Witcraft, Aimee L McRae-Clark, Kathleen Brady, Courtney King, Constance Guille
Peripartum cannabis use can be harmful to pregnant individual's and children's health, yet it is the most used illicit substance during the peripartum period. Despite the ability of some people to reduce and abstain from cannabis use during pregnancy, the first year postpartum is a high-risk time for returning to cannabis. However, characterization of cannabis use patterns in the peripartum period
-
Integrative Treatment for Substance Use Disorders: Improving Outcomes Through Evidence-based Practice of Yoga-derived Breathwork and Meditation. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-23 Ameya Krishnan
Among 20.4 million US adults diagnosed with substance use disorders (SUDs), up to 60% return to use despite treatment or attempted abstinence. Standard care for SUDs is pharmacotherapy and/or behavioral interventions in either an inpatient or outpatient setting. Both national and international epidemiological data suggest this approach to treatment is insufficient and use of an integrative protocol
-
Evaluation and Management of Buprenorphine Extended-Release Injection Thrombophlebitis: A Case Report. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-16 John Barrett, Rebecca Schapiro, Emily Casey, Judy Chertok
Buprenorphine extended-release subcutaneous injection (BUP-XR) is a medication used to treat opioid use disorder. It is a long-acting formulation of buprenorphine, which is a partial opioid agonist. Buprenorphine extended-release subcutaneous injection is injected into the subcutaneous space forming a depot that can last up to a month. The most common adverse effects of BUP-XR are injection site pain
-
An Inpatient Protocol for the Treatment of Methamphetamine Withdrawal in Patients with and without Opioid Use Disorder. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-16 Timothy E Wilens, Ronan L H Wilson, Lia Beltrame, Adam Taylor, James O'Connell
Increasing rates of methamphetamine (METH) use, use disorders, and related overdoses are a growing public health problem. There are a lack of protocols addressing METH intoxication and withdrawal symptoms that manifest during acute withdrawal treatment resulting in inpatient management difficulties and premature discharges. This report presents a novel treatment protocol comprised of behavior-targeted
-
Evidence of "Repeated Admission Bias" Among Those Who Use Injection Drugs Across 2 Decades of US Treatment Admissions: 2000-2020. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-16 Nicholas L Bormann, Stephan Arndt
Encounter-based datasets like the Treatment Episode Dataset-Admissions (TEDS-A) are used for substance use-related research. Although TEDS-A reports the number of previous treatment admissions, a limitation is this reflects encounters, not people. We sought to quantify the methodologic bias incorporated by using all encounters versus initial encounters and assess if this risk is evenly distributed
-
Expanding Medical Education to Include Substance Use Disorders during Pregnancy and Postpartum: Preliminary Effectiveness of a Pilot Curriculum for Medical Students. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-11 Caitlin E Martin, Mariana Martinez Telleria, Kara Hostetter, Lillia Thumma, Cherie Edwards, Bhushan Thakkar
To effectively combat the simultaneous overdose and maternal mortality crises, a multimodal approach is needed. The aim of this study is to evaluate the preliminary effectiveness of a pilot, experiential learning, substance use disorder (SUD) curriculum embedded into a third-year medical student obstetrics and gynecology clerkship to improve self-reported confidence in SUD clinical skills.
-
Adolescent Tobacco/Nicotine Use and the Potential Role of Contingency Management-Based Interventions. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-10 Anaheed Shirazi, Niloofar Radgoudarzi, Arthur L Brody
The high prevalence of tobacco/nicotine use among youth, including e-cigarettes, is a public health problem in the United States. Early exposure leads to an increased risk of dependence and health consequences in adulthood. We reviewed the literature on current treatment approaches for nicotine/tobacco use in adolescents/young adults and highlighted underexplored areas of treatment research. There
-
Substance Use Overdose Deaths Among Black and Indigenous Women in Wisconsin: A Review of Death Certificate Data From 2018 to 2020. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-05 Alexa A Lopez, Jeneile M Luebke, Ryan Redner, Hanan Abusbaitan, Sergey Tarima
We are in the midst of an overdose epidemic that has grown during the concurrent COVID-19 pandemic. In Wisconsin, overdose deaths increased 11-fold from 2000 to 2020, with over 1200 deaths in 2020. Because of disparities in substance use initiation, relapse, and treatment success among racially minoritized women, this study's purpose was to investigate overdose death rates among Black and Indigenous
-
Responses to a "Typical" Morning Dose of Kratom in People Who Use Kratom Regularly: A Direct-Observation Study. J. Addict. Med. (IF 5.5) Pub Date : 2024-01-04 Kirsten E Smith, Jeffrey M Rogers, Abhisheak Sharma, Christopher R McCurdy, Stephanie T Weiss, Kelly E Dunn, Jeffrey D Feldman, Michelle A Kuntz, Sushobhan Mukhopadhyay, Kanumuri Siva Rama Raju, Richard C Taylor, David H Epstein
Use of kratom has outpaced systematic study of its effects, with most studies reliant on retrospective self-report.
-
Missed Opportunities: Substance Use Hotline Operator Uncertainty of State Buprenorphine Prescribing via Telemedicine. J. Addict. Med. (IF 5.5) Pub Date : 2023-12-21 Danielle F Haley, Eleanor R Agoos, Courtney R Yarbrough, Leslie W Suen, Leo Beletsky
We examined substance use hotline operator certainty of each US state and Washington, DC's endorsement of buprenorphine (initiation and continuation) prescribing via telemedicine.
-
Blood Oxygenation and Heart Rate Changes after Diamorphine Intravenous Injection during Opioid Agonist Treatment for Outpatients With Heroin Dependence. J. Addict. Med. (IF 5.5) Pub Date : 2023-12-21 Karina A Thiessen, Christoph Dilg, Christian G Schütz
More than 60 million people use opioids each year, and many countries have declared an opioid overdose crisis. Heroin, one of the most commonly used opioids, has depressant effects on autonomic functioning; however, few studies have been able to examine the effects of heroin or its pharmaceutically prepared equivalent, diamorphine, in human clinical populations. The present study examined heart rate
-
Clinical Implications of the Relationship Between Naltrexone Plasma Levels and the Subjective Effects of Heroin in Humans. J. Addict. Med. (IF 5.5) Pub Date : 2023-12-21 Felipe Castillo, Hannah M Harris, Dania Lerman, Adam Bisaga, Edward V Nunes, Zhijun Zhang, Melanie Wall, Sandra D Comer
Extended-release naltrexone (NTX) is an opioid antagonist approved for relapse prevention after medical withdrawal. Its therapeutic effect is dependent on the NTX plasma level, and as it decreases, patients may lack protection against relapse and overdose. Therefore, identifying the minimally effective NTX level needed to block opioid-induced subjective effects has important clinical implications.
-
The IMPACT (Infection Management Plus Addiction Care Together) Pilot: A Case Series of Combined Contingency Management for Substance Use Disorders and Antibiotic Adherence in the Hospital Setting. J. Addict. Med. (IF 5.5) Pub Date : 2023-12-18 Ayesha Appa, Stefan Baral, Brianna Stein, Kelly Knight, Monica Gandhi, Phillip Coffin, Marlene Martin
Psychostimulant-related mortality is rising alongside increasing substance use-related hospitalizations, which are commonly complicated by patient-directed (or "against medical advice") discharges. Contingency management (CM) is an underused evidence-based treatment for substance use disorders with proven efficacy to support medication adherence. Our objective was to describe feasibility and preliminary
-
Mortality in Treatment-seeking Older Adults Receiving Medications for Opioid Use Disorder. J. Addict. Med. (IF 5.5) Pub Date : 2023-12-12 Andrea N Weber, Stephan Arndt, Benjamin Miskle, Nicholas L Bormann
Older adults (OAs; age 55+ years) are increasingly seeking specialty treatment of opioid use disorder. Previous analyses of the Treatment Episode Data Set-Discharges (TEDS-D) database have reported higher rates of in-treatment mortality for those receiving medications for opioid use disorder (MOUD). We evaluate current trends in mortality for treatment-seeking OAs.
-
Maternal Perspective of Inpatient Methadone Initiation: Opportunities to Increase Retention in Treatment. J. Addict. Med. (IF 5.5) Pub Date : 2023-12-01 Meghan Gannon, Dennis Hand, Vanessa Short, Kimberly McLaughlin, Tara Flood, Kathryn Shaffer, Nicole Lenegan, Diane Abatemarco, Stephen DiDonato
Recent trends demonstrate increases in the rates of opioid use among pregnant and parenting women. Treatment for pregnant people with opioid use disorder (OUD) includes medications for OUD, like methadone, as well as comprehensive support services. Still, inpatient treatment engagement is suboptimal and treatment drop out is common. There is little research examining the maternal perspective of the
-
Pain Management in Patients With Opioid Use Disorder on Extended-release Buprenorphine: A Case Report. J. Addict. Med. (IF 5.5) Pub Date : 2023-12-01 Anna-Maria South, Devin Oller, Michelle Lofwall, Laura C Fanucchi
Persons with opioid use disorder (OUD) are receiving extended-release buprenorphine (ER-buprenorphine) for treatment of OUD. There are no clinical guidelines for management of patients with OUD on ER-buprenorphine experiencing acute or chronic pain. This case report describes 3 patient-involved, multidisciplinary approaches for pain management in various clinical scenarios, including a scheduled knee
-
Expert Views on State Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder: A Qualitative Analysis of an Online Modified Delphi Process. J. Addict. Med. (IF 5.5) Pub Date : 2023-12-01 Sean Grant, Rosanna Smart, Adam J Gordon, Rosalie Liccardo Pacula, Bradley D Stein
The aim of this study was to examine expert views on the effectiveness and implementability of state policies to improve engagement and retention in treatment for opioid use disorder (OUD).
-
Parent Guidance on Alcohol Use for Youth With Chronic Medical Conditions. J. Addict. Med. (IF 5.5) Pub Date : 2023-11-30 Jessica B Calihan, Machiko Minegishi, Sharon Levy, Elissa R Weitzman
Youth with chronic medical conditions are vulnerable to unique alcohol-related health consequences, yet there are few prevention strategies targeting this group. Youth with chronic medical conditions parents' beliefs and provision of alcohol-related guidance have not yet been explored, which limits the development of effective family-based interventions.
-
Xylazine-associated Wounds: Clinical Experience From a Low-barrier Wound Care Clinic in Philadelphia. J. Addict. Med. (IF 5.5) Pub Date : 2023-11-29 Rachel McFadden, Sara Wallace-Keeshen, Kristi Petrillo Straub, Rebecca A Hosey, Rachel Neuschatz, Keara McNulty, Ashish P Thakrar
The veterinary sedative xylazine is spreading in unregulated opioid supplies across North America. Among people who use drugs with repeated exposure to xylazine, a distinct wound type has emerged. Here, we describe these wounds and share our experience treating them in a nurse-led, low-barrier wound care clinic in Philadelphia, PA. We propose a reimagining of wound treatment across settings to better
-
Initiatives to Support the Transition of Patients With Substance Use Disorders From Acute Care to Community-based Services Among a National Sample of Nonprofit Hospitals. J. Addict. Med. (IF 5.5) Pub Date : 2023-11-27 Noa Krawczyk, Bianca D Rivera, Ji E Chang, Zoe Lindenfeld, Berkeley Franz
Hospitals are a key touchpoint to reach patients with substance use disorders (SUDs) and link them with ongoing community-based services. Although there are many acute care interventions to initiate SUD treatment in hospital settings, less is known about what services are offered to transition patients to ongoing care after discharge. In this study, we explore what SUD care transition strategies are
-
Dispensing Methadone at Hospital Discharge: One Hospital's Approach to Implementing the "72-hour Rule" Change. J. Addict. Med. (IF 5.5) Pub Date : 2023-11-22 Emily Skogrand, Jackie Sharpe, Honora Englander
Methadone for opioid use disorder treatment in ambulatory settings is restricted to federally licensed opioid treatment programs (OTPs) in the United States. However, these restrictions do not apply during hospitalization. A recent change to the rule governing methadone in non-OTP settings created an opportunity to dispense methadone at hospital discharge for up to 72 hours.
-
Mutual Mistrust: The Multilayered Experiences at the Intersection of Healthcare and Early Parenting among Mothers with Opioid Use Disorder. J. Addict. Med. (IF 5.5) Pub Date : 2023-11-22 Davida M Schiff, Serra Muftu, Kathryn Dee L MacMillan, Erin C Work, Bettina B Hoeppner, Shelly F Greenfield, Leah Schwartz, Barbara Chaiyachati, Timothy E Wilens, Judith A Bernstein
The aim of the study is to explore the early parenting experiences among a cohort of postpartum individuals with opioid use disorder (OUD) both during and after the delivery hospitalization to identify areas of intervention to strengthen bonding and attachment.
-
Priorities for Well Child Care of Families Affected by Parental Opioid Use Disorder. J. Addict. Med. (IF 5.5) Pub Date : 2023-11-22 Neera K Goyal, Erica Sood, Meghan A Gannon, Grace Harris, Dennis J Hand, Diane J Abatemarco, Vanessa L Short
Parenting women in treatment for opioid use disorder (OUD) report a lack of family centeredness and anticipatory guidance within well child care (WCC), and WCC utilization is low among affected children. We explore priorities for WCC visit content to inform primary care recommendations for this population.
-
A Brief Online Training to Address Pharmacists' Willingness to Dispense Buprenorphine. J. Addict. Med. (IF 5.5) Pub Date : 2023-11-10 Delesha Carpenter, Patricia Mashburn, Cheryl Viracola, Grace Marley, Bayla Ostrach
The recent passage of the Mainstreaming Addiction Treatment (MAT) Act could increase the number of patients seeking to fill buprenorphine prescriptions at community pharmacies; however, multiple barriers limit community pharmacists' ability and willingness to dispense buprenorphine. We assess whether a brief online buprenorphine training program (Buprenorphine Understanding in the Pharmacy Environment)
-
All a-BORG! The Dangerous Drinking Trend Steamrolling Across Social Media and College Campuses. J. Addict. Med. (IF 5.5) Pub Date : 2023-11-01 Nicholas Pratt, Ricky Madhavan, Paul Weigle, Jeremy Weleff
Black out rage gallons (BORGs) are a troublesome drinking pattern emerging on social media platforms. The prevalence of BORGs has been increasing on college campuses and is demonstrating significant consequences. There is no known research on BORGs in addiction treatment settings. We suggest that future research will be necessary to understand their implication. Troublesome binge drinking is not a
-
Research Priorities to Improve Treatment of Patients Exposed to Xylazine-fentanyl: Rapid Communication from a National Institute on Drug Abuse Center for the Clinical Trials Network Meeting. J. Addict. Med. (IF 5.5) Pub Date : 2023-10-24 Rachel Haroz,Kristen Huntley,Jeanmarie Perrone
In response to the rapid escalation in the detection of xylazine in the unregulated drug supply, in April 2023, the White House designated fentanyl contaminated with xylazine an "emerging threat." The National Institute on Drug Abuse Center for Clinical Trials Network convened a multidisciplinary meeting of stakeholders, federal staff members, researchers, and clinicians caring for patients with fentanyl
-
Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons With Opioid Use Disorder: A Case Series. J. Addict. Med. (IF 5.5) Pub Date : 2023-10-24 Elizabeth Rose Hansen,Anna Maria South,Michelle R Lofwall,Laura C Fanucchi
INTRODUCTION Monthly subcutaneous injectable buprenorphine (XR-Bup) is an option for treatment of opioid use disorder (OUD) that addresses some sublingual buprenorphine adherence barriers and is infrequently offered to hospitalized patients with OUD. METHODS A retrospective case series was performed for patients receiving XR-Bup upon discharge from 1 academic medical center. Demographic information
-
Generative Artificial Intelligence Tools in Medicine Will Amplify Stigmatizing Language. J. Addict. Med. (IF 5.5) Pub Date : 2023-10-20 Steven Tate
-
Stigma in Large Language Models: A Chatbot Responds. J. Addict. Med. (IF 5.5) Pub Date : 2023-10-20 Scott G Weiner,Sarah E Wakeman
-
Low-dose Induction of Buprenorphine in Pregnancy: A Case Series. J. Addict. Med. (IF 5.5) Pub Date : 2023-10-20 Sue Junn, Nicol Tugarinov, Katrina Mark
Because of a risk of precipitated withdrawal occurring from buprenorphine induction in people who use fentanyl, low-dose inductions are becoming increasingly common. However, little evidence exists on the use of this method in pregnant people.
-
Residential Treatment Exclusively for Tobacco Use Disorder: A Narrative Review. J. Addict. Med. (IF 5.5) Pub Date : 2023-10-17 Symen Kornelis Spoelstra, Robert C van de Graaf, Arie Dijkstra
Tobacco use disorder is a major public health issue, and novel smoking cessation approaches are urgently needed. Residential treatment programs have been suggested as a potentially effective treatment for tobacco use disorder. However, there is limited literature on residential treatment programs for patients who are exclusively dependent on nicotine.
-
Evaluation of Low-dose Buprenorphine Initiation With Buprenorphine Buccal Films in Hospitalized Patients: A Retrospective Cohort Study. J. Addict. Med. (IF 5.5) Pub Date : 2023-10-17 Serena Arnouk, Jeffrey R Wunderlich, S Alex Sidelnik
Low-dose buprenorphine initiation (LDBI) strategies to transition patients from full opioid agonists to buprenorphine have previously been described using sublingual films, intravenous solution, transdermal patches, and, more recently, buccal films. The objective of this study was to describe the effectiveness of LDBI using novel titration schedules with buccal films.
-
48-hour Induction of Transdermal Buprenorphine to Extended-release Buprenorphine. J. Addict. Med. (IF 5.5) Pub Date : 2023-10-17 Pouya Azar, James S H Wong, Nickie Mathew, Martha J Ignaszewski, Nilufar Partovi, Reinhard M Krausz, Adedayo Ajidahun, Sahithi Thotakura, Marianne Harris, Rolando Barrios, Julio S G Montaner, Anil R Maharaj
Buprenorphine extended-release (BUP-XR) provides sustained delivery of buprenorphine to control withdrawal and craving symptoms in the form of a monthly injectable and has been shown to improve health outcomes in patients with opioid use disorder. It is recommended that patients are stabilized with a transmucosal buprenorphine product, for at least 7 days per the product monograph; however, clinically
-
Agreement Between Self-reports and Urine Toxicology Measures of Illicit Methamphetamine and Cocaine Use During Early Pregnancy. J. Addict. Med. (IF 5.5) Pub Date : 2023-10-06 Ayesha C Sujan, Stacey E Alexeeff, Natalie E Slama, Nancy Goler, Lyndsay A Avalos, Sara R Adams, Amy Conway, Deborah Ansley, Anish Pal, Rachel L Gunn, Lauren Micalizzi, Kelly C Young-Wolff
This study aimed to assess agreement between self-report and urine toxicology measures assessing use of 2 illicit simulants (methamphetamine and cocaine) during early pregnancy.
-
Withdrawal-like Symptoms in Problematic Pornography Use: A Scoping Review. J. Addict. Med. (IF 5.5) Pub Date : 2023-10-03 Thiago Henrique Roza, Lucas Tavares Noronha, Augusto Ossamu Shintani, Raffael Massuda, Felix Henrique Paim Kessler, Ives Cavalcante Passos
There is still debate whether problematic pornography use (PPU) can be understood as an addictive disorder, and little is known about withdrawal-like symptoms in these patients. Therefore, our aim was to summarize the existing scientific literature about this topic in the format of a scoping review.
-
Establishing a Protocol for Determining the Costs of an Integrated Set of Evidence-based Practices Aimed at Reducing Opioid Overdose Deaths. J. Addict. Med. (IF 5.5) Pub Date : 2023-09-28 Yjuliana Tin, Mathieu Castry, Rachel Bowers-Sword, Shruti Shantharam, Arnie Aldridge, Gary A Zarkin, Laura Starbird, Benjamin P Linas, Joshua A Barocas, Jake R Morgan
In the midst of the opioid overdose crisis, local jurisdictions face a choice of public health interventions. A significant barrier when considering evidence-based practices (EBPs) is the lack of information regarding their implementation cost. This protocol paper provides the methodological foundation for the economic cost evaluations of community-wide strategies on the scale of a national study.